Oslo, 12 February 2025 - For the full year 2024, Navamedic ASA (OSE: NAVA), a
Nordic pharma company and reliable provider of high-quality products to
hospitals and pharmacies, delivered revenues of NOK 531.3, which is 3.8 per cent
up from 2023. Adjusted EBITDA amounted to NOK 46.6 million, compared to NOK 51.5
million last year. Gross margin ended at 39.3 per cent, up from 38.9 per cent in
2023.

The results are largely explained by strong growth in the Consumer Health
segment and the NOK 22.7 million milestone payment following the agreement with
Orion Corporation to market and sell Flexilev® and OraFID® in Europe.
Additionally, the Hospital segment has performed well throughout the year,
whilst the Prescription Drugs (RX) segment has delivered lower sales.

"The past year has been transformative for Navamedic. We have invested in
several growth initiatives such as marketing campaigns for Mysimba® and Eroxon®,
regulatory investments for new products and upcoming launches, as well as
streamlined the organisation for future growth. As a result, we have an even
stronger and diversified product portfolio and a highly capable team.

"In addition, we have several exciting product launches coming up in 2025 across
all segments with Eroxon®, Flexilev® in OraFID® and new medical nutrition and
antibiotic products," said Kathrine Gamborg Andreassen, CEO of Navamedic.

Key figures and category update for the fourth quarter of 2024

Navamedic delivered revenues of NOK 131.2 million in the fourth quarter, which
is 4.7 per cent up from the corresponding quarter in 2023. Adjusted EBITDA
amounted to negative NOK 3.2 million, compared to NOK 7.9 million last year.
Gross margin ended at 33.7 per cent, down from 36.5 per cent in the fourth
quarter of 2023. Operating results (EBIT) for the fourth quarter of 2024
amounted to negative NOK 14.4 million, compared to NOK 0.9 million in 2023.
Operating costs ended at NOK 47.4 million, compared to NOK 37.8 million last
year. Net financial items ended at negative NOK 7.4 and profit before tax was
negative NOK 21.8 million.

The negative EBITDA in the quarter was impacted by marketing spending,
regulatory investments, and some one-off COGS items.

As part of the Prescription Drugs (RX) category, sales of Mysimba® increased by
8 per cent quarter-over-quarter (QoQ), whilst Imdur® delivered lower sales due
to it being out-of-stock.  Nitrolingual® saw lower sales because of increased
market competition. Forlax® had a strong quarter and was up 39 per cent year
-over-year (YoY) and 54 per cent QoQ. Flexilev® has had a strong year with a 48
per cent increase YoY, whilst the quarter has seen a 32 per cent decrease in
sales.

The Consumer Health business area delivered more than 20 per cent growth YoY.
With the launch of Eroxon® in Finland in November, Navamedic has invested in
successful promotional activities. Eroxon® is expected to be launched in Denmark
in Q2 2025. Modifast continues to deliver strong sales and experienced a 21 per
cent increase in sales YoY. ThermaCare, Absolut Torr, GeloRevoice stand out with
strong sales figures both YoY and QoQ.

The Hospital category delivered steady results in the quarter and Navamedic is
expecting new and innovative product launches for both Medical Nutrition and
Antibiotics in 2025. The additional tender wins for the antibiotic's portfolio
in 2024 are expected to drive income growth as of the first quarter of 2025.
Moving forward, Navamedic will continue to expand and secure market access for
new antibiotics in the Nordics and the Netherlands and consider new
opportunities for market expansion in additional Northern European countries.

Outlook

Navamedic continues to see strong growth and new expansion opportunities and
reiterates its mid-term ambition of building a NOK 1 billion revenue company.

"Though the fourth quarter has been more challenging than previous quarters,
Navamedic has ended 2024 in a strong position. We have a diversified portfolio
in place with several high performing products. With new product launches in the
pipeline, we are confident that we will achieve strong results in the coming
quarters," Andreassen concluded.

Presentation

Navamedic will present the results for the fourth quarter and full year 2024 at
08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the
presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be
webcast at the following link:

https://navamedic.com/investors/financial-results/

Note: EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section in the
attached presentation.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62 842

E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's
quality of life by being a reliable supplier of high-quality prescription,
consumer health, and hospital products to hospitals and pharmacies. Our growing
product portfolio has been carefully selected to meet current public health
concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to
empower people to live healthier and more fulfilling lives.

What sets us apart is our deep-rooted commitment to understanding the needs and
requirements of the countries where we are present. Our local insight and
competence enable us to understand the specific needs of each country where we
operate and ultimately to gain market access. This makes us a preferred partner
for international companies expanding their footprint across the Nordics and
Benelux regions, through either in-licensing or out-licensing. Navamedic has
been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is

headquartered in Oslo, Norway.

For more information, please visit Navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.